7-OH: who wants it scheduled, who does not, and what the record shows about the money
7-hydroxymitragynine, usually shortened to 7-OH, is one of the alkaloids in the kratom plant. The Drug Enforcement Administration describes its place in the leaf this way: “In its natural botanical form, 7-hydroxymitragynine makes up less than two percent of the total alkaloid content or occurs in trace amount in M. speciosa.”[1] The products the federal government has moved against are not leaf. They are the concentrated forms, which the FDA listed as “including tablets, gummies, drink mixes and shots” when it announced its position in July 2025.[2]
This page records who is pushing the federal action, who is resisting it, and what money each side has disclosed. Positions and finances can be documented from filings and primary records, and they are below. Motives cannot be documented. Where a named outlet or official has alleged one, it appears here as that person's allegation, with its date.
What the government has done, in order
July 15, 2025. The FDA said it had sent warning letters to seven companies for selling 7-OH products, in its words “seven recent warning letters sent to companies for illegally marketing products containing 7-hydroxymitragynine, also known as 7-OH”.[3]
July 29, 2025. The FDA recommended that 7-OH be scheduled. Its release drew the line that every later document repeats: “The FDA is specifically targeting 7-OH, a concentrated byproduct of the kratom plant; it is not focused on natural kratom leaf products.”[2] Commissioner Marty Makary said that “7-OH is an opioid that can be more potent than morphine”.[2] Health Secretary Robert F. Kennedy Jr. described his own heroin use at the briefing and, per Axios, said of the past that he “had to go to the South Bronx or the Lower East Side. But now you can go to any gas station”.[4]

Figure 1. The FDA release of July 29, 2025. Its second paragraph draws the line every later document repeats: concentrated 7-OH is the target, natural kratom leaf is not.[2]
September 2, 2025. Ohio's governor paused a planned state kratom ban. The Ohio Statehouse News Bureau reported that “Gov. Mike DeWine is pausing his call for a ban on kratom after a conversation with Health and Human Services Secretary Robert F. Kennedy Jr.”[5] That call became part of a corruption allegation nine months later, below.
December 2, 2025. The FDA announced that the U.S. Marshals Service had “seized approximately 73,000 units of 7-hydroxymitragynine (7-OH) products” from three Missouri firms.[6]
March 2026. Eleven senators, led by Pete Ricketts and Richard Blumenthal, wrote to Makary asking for more than 7-OH: “However, we encourage you to consider scheduling the whole kratom leaf, given that some of the most accessible and addictive products contain whole kratom leaf, not 7OH.”[7] The next day Representative Gus Bilirakis introduced H.R. 8000, the END 7-OH Act, which would schedule synthetic 7-OH while exempting the compound as it occurs in the plant.[8] Senator Roger Marshall had been pressing DEA since October 2025 with a different comparison: “Its pharmacology more closely resembles that of fentanyl than any traditional botanical supplement, and its risk profile poses a grave threat to public health.”[9]

Figure 2. The senators’ letter of March 18, 2026, first page. Its second paragraph asks the FDA to consider scheduling the whole leaf, which no federal document since has proposed.[7]

Figure 3. H.R. 8000 as introduced on March 19, 2026. The long title limits the bill to synthetic 7-hydroxymitragynine.[8]
May 11, 2026. President Trump said the administration was “looking very seriously at natural 7-OH and getting that approved”.[10] Nobody agreed on what that meant. Pain News Network reported that “A HART news release said the president was endorsing all forms of 7-OH, even the concentrated products that contain as much as 96% 7-OH.”[10] The American Kratom Association read it as an endorsement of leaf.[10]
July 6, 2026. DEA published two notices of intent. The first, docket DEA-1570, proposes placing 7-OH in Schedule I only above a threshold. Leaf is covered when it “contains more than 0.050 percentage of 7-hydroxymitragynine on a dry weight basis”, and any other article when the compound is present at “greater than 0.050 percentage by weight/weight, weight/volume, or volume/volume or greater than 1.00 milligram of 7-hydroxymitragynine in the article”.[1] The notice records that HHS answered DEA on March 6, 2026, and that “there were currently no investigational new drug applications (IND) or approved new drug applications (NDA) for these substances.”[1] It said the order “will not be issued before August 5, 2026”.[1] The second notice, docket DEA-1644, covered three related compounds that do not occur in the plant: mitragynine pseudoindoxyl, MGM-15 and MGM-16.[11] HHS opened its own docket the same day, on the threshold alone: “Note that OASH is not soliciting comment on any permanent scheduling decision, the general safety or utility of kratom-derived products, or other policy questions outside the scope of the threshold determination for temporary scheduling.”[12] Kennedy's statement that week said “HHS reviewed the science and recommended this action.”[13] The same release said “These actions are not intended to regulate natural leaf kratom that does not contain enhanced levels of 7-OH.”[13]

Figure 4. The DEA notice of intent as published, 91 FR 40917. The thresholds are in the middle column: 0.050 percent by dry weight for leaf, and 0.050 percent or 1.00 milligram for any other article.[1]

Figure 5. The HHS release of July 1, 2026, as archived. It describes two notices of intent, one on 7-OH above a threshold and one on three synthetic derivatives.[13]
August 26, 2026. DEA issued the order for the three derivatives. “This temporary order is effective August 26, 2026, until August 26, 2028.”[14] The Justice Department's release said “This action is directed at deliberately manufactured and concentrated opioid products, not traditional botanical kratom.”[15] The order says nothing about 7-OH itself.[14] The same day, HHS extended its threshold docket and asked the public to “Submit either electronic or written comments, data, or information by September 10, 2026.”[16]

Figure 6. The page where the DEA order on the three derivatives begins, right-hand column. Its DATES line runs the order from August 26, 2026 to August 26, 2028. The title names three substances and not 7-OH.[14]
September 30, 2026. STAT reported that the DEA had not acted “after an extended public comment period ended on Sept. 10 with nearly 36,000 submissions”.[17]
October 7, 2026. Senators Chuck Grassley, Susan Collins and Mike Lee wrote to DEA Administrator Terrance Cole and acting FDA Commissioner Kyle Diamantas. They asked the two agencies “to consider scheduling the entire kratom plant, including all levels of 7-OH (not simply the threshold limit as stated in the Notice of Intent)”.[18] They also asked for speed: “It is imperative that the final emergency scheduling order for 7-OH be expeditiously promulgated.”[18]
October 8 and 9, 2026. HHS went the other way and recommended a higher line. DEA's new 7-OH notice rests on a letter from the Assistant Secretary for Health, Admiral Brian Christine, which it dates October 8, the day after the senators wrote.[19] The companion notice on MGM-15 and MGM-16, published the same day, cites an HHS letter on pseudoindoxyl and dates it October 6.[20] Neither notice says whether that is one letter or two. HHS announced the change on October 9, with a line from Kennedy: “We are drawing a clear line between natural kratom and dangerous, enhanced opioid products”.[21] The release says what prompted it. After the August order, “Since then, questions have emerged about how scheduling could affect natural botanical kratom products potentially containing trace amounts of MGPI.”[21] MGPI is the release's abbreviation for mitragynine pseudoindoxyl, which the August order had scheduled at any level.[21][14] On the new ratio test it says “The ratio-based approach reflects the alkaloid composition of natural kratom products and provides a way to identify products intentionally enhanced or concentrated with 7-OH or MGPI.”[21]

Figure 7. The HHS release of October 9, 2026, as archived. The two bullets are the two prongs of the new threshold. Either one is enough to bring a product under Schedule I.[21]
October 14, 2026. DEA published two new notices of intent. Neither is an order. The first, 91 FR 65370, replaces the July proposal and adds pseudoindoxyl to it. It would place 7-OH and pseudoindoxyl in Schedule I when either one, or the two combined, is above a threshold with two prongs, and either prong is enough.[19] The first prong is concentration: “greater than 1 mg per gram (for solid powders, encapsulated material, or other solid forms) or greater than 1 mg per milliliter (for liquid preparations)”.[19] The second is a ratio. A product is covered when its mitragynine, divided by its 7-OH and pseudoindoxyl, comes to less than 100.[19] By our arithmetic, July's 0.050 percent is 0.5 mg per gram, so the line for solids has doubled.[1][19] July's cap of 1.00 milligram per article is gone, and the ratio is new.[1][19] CBS's 60 Minutes, on November 15, described the change as “increasing the amount of 7-OH allowed in products by 20-fold”.[22] Neither notice gives a factor, and the broadcast did not say what it compared. Against July's per-article cap the factor depends on the size of the product: by our arithmetic, a 20-gram product could hold 20 milligrams under the new line where July allowed 1.[1][19]
The notice is direct about what a higher line means: “While the new threshold recommended by HHS would permit certain products to remain in the marketplace without being subject to schedule I controls, neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels.”[19] Until a new order is printed, pseudoindoxyl stays where August put it, with no threshold. DEA says the August order “remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn”.[19] The second notice, 91 FR 65381, keeps the other two derivatives exactly as they were: “Today, DEA is providing notice of its intent to publish a new temporary order for MGM-15 and MGM-16 that will maintain the temporary placement of these substances in schedule I of the CSA without change.”[20] There is no threshold for either.[20]

Figure 8. The proposed threshold in the copy DEA filed on October 9, 2026 for publication on October 14. This is the filed copy, not the printed page. It is still a notice of intent.[19]
The 7-OH notice gave a date: “The temporary scheduling order will be published in the Federal Register on or after November 13, 2026.”[19] As of November 18 it has not been. A search of the Federal Register for 7-hydroxymitragynine returns seven documents from 2026, and the two October notices are still the newest.[23] The notice also says, of the July proposal, “DEA is withdrawing that notice of intent elsewhere in this issue of the Federal Register.”[19] The search finds no withdrawal in the October 14 issue or since.[23] Until one is printed, the July notice has not been withdrawn on the record.
The notice is not consistent about the July date either. Its summary refers to “the July 7, 2026 notice of intent”, and a footnote says “On July 6, 2026, DEA published a notice of intent to place” 7-OH above a threshold.[19] The Federal Register dates the July notice July 6.[1]
October 2026, Louisiana. Louisiana's health secretary, Bruce D. Greenstein, signed a declaration of emergency adding mitragynine pseudoindoxyl, MGM-15 and MGM-16 to the state's Schedule I. It reaches any material containing any quantity of them, with no threshold.[24] So in the same month, the federal proposal would move pseudoindoxyl from any amount to a threshold, and Louisiana fixed it at any amount.[19][24]
Cities and counties have started writing their own 7-OH rules underneath the federal notices. Philadelphia (/p/311), Hillsborough County (/p/310) and Irvine (/p/312) each have a News post written from the local text, and our article on local bans reads all three clause by clause.
November 16, 2026. Grassley wrote again, this time with Collins, Rick Scott, Mike Crapo, Bill Cassidy, Jerry Moran, Shelley Moore Capito and James Risch. Their objection is the new line: “Kratom is a drug in any form with addictive properties, and we believe this combined threshold level for 7-OH and MP set by DEA is inappropriately high and unsound”.[25] They write that the new actions “double the previously allowable limit for 7-OH, raising it from 0.05% to 0.1%”.[25] They asked the FDA for the evaluations behind the higher threshold and asked DEA to go back to the July line. The letter closes: “We look forward to your reply no later than November 30, 2026.”[25]
The letter describes more than DEA has done. It says “DEA then withdrew these actions, ultimately setting a more permissive 7-OH limit”, and it calls the July notice an order.[25] The Federal Register holds two notices of intent and no printed withdrawal.[23] By DEA's own account, the August order on pseudoindoxyl is still in effect.[19] The letter is a record of what eight senators asked for. It is not a record of what DEA did.
Whatever DEA prints next will be hard to challenge in court. The Congressional Research Service explains why: “Unlike permanent administrative scheduling, temporary scheduling is not subject to judicial review.”[26] The lawsuits described below ask courts how to read the August order, not to strike it down.[27][28]

Figure 9. The Congressional Research Service sidebar of July 17, 2026, which explains why temporary scheduling is hard to challenge in court.[26]
The sides, and what each discloses
| Organisation | Legal form | Latest revenue on Form 990 | Wants 7-OH concentrates scheduled | Wants leaf kept legal |
|---|---|---|---|---|
| American Kratom Association | 501(c)(4) | Revenue $4,700,427 (year ending December 2024)[29] | yes[30] | yes[30] |
| Global Kratom Coalition | 501(c)(6) | Revenue (2024): $3,431,756[31] | yes[32] | yes[32] |
| Holistic Alternative Recovery Trust (HART) | 501(c)(4) | Revenue (2024): $406,300[33] | no[34] | not its issue |
| Stop Gas Station Heroin LLC | lobbying client | not a nonprofit; paid $750,000 to one firm[35] | yes[35] | yes[35] |

Figure 10. The American Kratom Association’s Form 990 figures as ProPublica presents them. Revenue grew from almost nothing in 2014 to $4.7 million in 2024.[29]
The two largest kratom trade groups are on the government's side of the 7-OH question. Pain News Network summarised the American Kratom Association's position on the day of the DEA notice: “The AKA has been lobbying local governments to ban 7-OH, but keep kratom legal.”[30] Its lead lobbyist Mac Haddow, described by the Tampa Bay Times in 2023 as “a former Reagan administration official”,[36] put the group's view this way: “The 7-OH industry created this crisis. They manufactured or distributed high-potency opioid products, dressed them up as kratom, and then tried to force natural kratom consumers to pay the price for their recklessness.”[30] The association's nonprofit arm has also funded kratom research. ProPublica reported that “The AKA, through its nonprofit arm, the Center for Plant Science and Health, has donated more than $100,000 to the school.”[37] The school is the University of Florida.[37]
The association has sued, from the pro-scheduling side, and it is one of three plaintiffs with the same lawyers. A joint status report in its case says the suit was filed in the District of Columbia on August 26, 2026, the day the order on the three derivatives was published.[38][14] The same report says that on that day the association's counsel filed a similar suit in Wyoming for Martin Sales Inc.[38] The association announced its own suit a day later, asking that the order not be applied to leaf carrying trace amounts of the derivatives: “The complaint names the Drug Enforcement Administration, DEA Administrator Terrance C. Cole, and the U.S. Department of Justice as defendants.”[28] The status report has a footnote on the third case: “Counsel for Plaintiff filed similar claims against the same defendants on behalf of a different” plaintiff, New Hope Botanicals, in California.[38] Kilpatrick Townsend & Stockton signs for the plaintiffs in both the Washington and California filings.[38][27]
New Hope's complaint, filed in the Central District of California on August 31, is explicit about its aim: “Plaintiff does not ask the Court, in the first instance, to invalidate the Temporary Scheduling Order.”[27] It asks for a declaration that the order does not reach traditional kratom. It defines that as powder and extract “that maintain the same alkaloid ratios as those found in the natural plant”, with at least 100 parts mitragynine for every part of 7-OH and pseudoindoxyl combined.[27] Five weeks later HHS recommended a ratio on the same terms: mitragynine against 7-OH and pseudoindoxyl, with the line at 100.[21][19] The record shows the same number in both documents, and their dates. It does not show that one led to the other.
The government did not appear at the first status conference in New Hope's case. The judge's minutes of September 28 record: “There was no one present for Defendants.” They go on: “The Court continues the status conference to October 5, 2026”.[39] In the Washington case the parties jointly proposed a briefing schedule that would end with the government's reply on October 7.[38]
The Global Kratom Coalition takes the same position as the association. NutraIngredients describes it as “an industry group founded by Ross in 2024 to advocate for traditional leaf kratom and against synthetic 7-OH”.[40] Ross is Jerry Ross of Botanic Tonics. A Florida Politics opinion column put it more sharply: “Ross, the founder of the Global Kratom Coalition, is best known as the founder of Botanic Tonics, manufacturer of the massively successful kava shot Feel Free.”[41] The coalition's executive director, Matthew Lowe, endorsed H.R. 8000 as a bill “which embraces existing federal health policy and widespread scientific consensus on the dangers posed by concentrated synthetic 7-OH opioid products”.[32] Its registered federal lobbying ended before the DEA notice. Legis1 reported that the coalition “terminated its lobbying relationship with BGR Government Affairs LLC effective May 1”.[42]
The larger lobbying spend ran through a differently named client. Lobbying Disclosure Act filings show Checkmate Government Relations reporting income from a client called Stop Gas Station Heroin LLC on kratom issues.[43] Legis1 added the quarters up as “totaling $750,000 across the engagement” and quoted the client's spokesperson: “Stop Gas Station Heroin advocates for stronger regulation of dangerous concentrated synthetic 7-hydroxymitragynine products”.[35] The New York Times reported that Ross backed the group.[44]

Figure 11. The lobbying report for the fourth quarter of 2025. Stop Gas Station Heroin LLC paid Checkmate $300,000 that quarter for work on kratom before Congress, HHS, the White House and the FDA.[43]
On the other side, HART is described by Pain News Network as “an advocacy group funded by 7-OH manufacturers”.[45] Its response to the DEA notice made two claims. The first is about evidence: “No confirmed deaths have been attributed solely to 7-OH.”[34] The second is about motive: “We are concerned this was never truly about public safety, but about market share.”[34] That second sentence is HART's allegation, made on July 2, 2026, by a party with a commercial interest in the outcome. HART organised a comment campaign and reported on July 30 that “more than 24,300 Americans have submitted public comments”.[46] A second consumer group, the 7-HOPE Alliance, reported “more than 30,000 comments submitted to the federal docket and more than 65,000 people signing a Change.org petition”.[47] The R Street Institute, which has no product to sell, filed a comment that accepted a problem and rejected the remedy: “It does not support temporary Schedule I placement at the proposed threshold.”[48]
The money, the allegations, and the pharmaceutical question
The documented financial interest in this fight belongs to a kratom company, not a drug company.
On May 19, 2026 the Daily Beast reported, from a filing with the Office of Government Ethics, that Homeland Security Secretary Markwayne Mullin's disclosure “shows he holds between $500,000 and $1 million in Botanic Tonics LLC”.[49] A department spokesperson told the outlet that Mullin “acts to ensure full compliance with all ethics and conflict of interest rules”.[49]
On June 15, 2026 the New York Times, in an investigation by Kenneth P. Vogel and Christina Jewett, reported the same stake and connected it to policy: “In a disclosure statement, he listed an investment worth as much as $1 million in a kratom company, Botanic Tonics, that could benefit from the changes he has sought.”[44] The Times also reported the Ohio call and what followed it: “Kennedy, as health secretary, called the governor of Ohio to try to head off a state ban on kratom in the fall of 2025. Months later, Botanic Tonics donated $1 million to a political committee associated with Kennedy.”[44] The department said Mullin “follows all ethics and conflict of interest standards and has not lobbied for any individual or company”.[44] The Times noted that “The Health and Human Services Department and Kennedy did not respond to requests for comment, nor did Ross.”[44] These are the Times's findings, published on that date, and they have not been tested in any proceeding.
On August 3, 2026 Senator Ron Wyden, the ranking member of the Senate Finance Committee, wrote to Ross. The letter calls Mullin's position ‘This is corruption.’[50] It describes the DEA notice as the outcome Mullin wanted, one that would clear shelves “so that your products gain market share and his investment soars”, and adds “I am concerned that this announcement is grounded in politics rather than in science.”[50] That is a senator's allegation on committee letterhead, not a finding. The committee's release noted in passing that on May 12, 2026 “Dr. Marty Makary resigned from his role as FDA Commissioner after repeatedly arguing against FDA approval of flavored vapes.”[51]

Figure 12. Senator Wyden’s letter of August 3, 2026, first page. It reproduces a banner from the Feel Free website and calls the banner’s claim false. The letter is a senator’s allegation, not a finding.[50]
On October 28, 2026 the New York Times published a story by Christina Jewett under the headline “Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying”. We read it in a syndicated copy.[52] The story is about pseudoindoxyl, the compound the August order scheduled at any amount and the October notice would allow below a threshold.[14][19] It sums up October in one line: “This month, the government reversed course.”[52] It links the change to David Gabbay, whom it describes as the manager of a large kratom distribution company who, “faced with evidence of the compound in products at the center of several wrongful death lawsuits against him, mounted a concerted lobbying push”.[52] It reports that he and his wife Maya gave to Republican candidates and committees through the year, “reaching about $2.9 million on Oct. 12”.[52] It describes the American Kratom Association as “an advocacy group funded heavily by the company Gabbay manages”, and reports that Mac Haddow “said he went to the White House to plead his case”.[52] Haddow told the paper he was “very satisfied” with the proposal and dismissed Gabbay's donations as a major factor.[52] The department's spokesperson, Emily Hilliard, said: “Neither litigation nor political contributions influenced HHS’ recommendation.”[52] The White House said that “any assertion that they may be based in anything other than scientific evidence is completely false.”[52] The paper wrote: “The Gabbays did not respond to requests for comment.”[52] These are the Times's findings. None of them has been tested in a proceeding, and we have not read the wrongful death suits.
The story's measure of the change came from a chemist. The amounts the new line would allow, it says, are “hardly traces”: “They are 25 to 500 times the levels currently found on the market, the senior author of a study cited by the Trump administration said in an interview.”[52] He is Amar Chittiboyina of the University of Mississippi. The paper reports that his team found about 2 parts per million in eight liquid products, and that he called the new line “too permissive.”[52] By our arithmetic the 500 holds for liquids: 1 milligram per millilitre is about 1,000 parts per million in a liquid about as dense as water.[19] The Times also reports that the level of pseudoindoxyl health officials adopted was the one suggested in a letter from Rahul Gupta, who led the White House drug policy office under President Biden. Gupta told the paper he wrote “in my own capacity” and was not paid by any litigant or industry group.[52]
Several of the story's facts can be checked against documents, and they match. The August order says “mitragynine pseudoindoxyl has been identified in at least 56 overdose cases, of which 48 were fatal events”, from February 2025 to May 2026. Those are the Times's 56 and 48.[14][52] The Justice Department's release of August 25 said the department “will exercise enforcement discretion when only incidental trace amounts of MGPI are confirmed in a product otherwise consistent with botanical kratom”.[15] The association sued on August 26, as the Times says.[38] New Hope Botanicals, one of the other two plaintiffs, licenses others to make products under its O.P.M.S. brand. Its complaint says that validated testing has found, or may find, “trace amounts of pseudoindoxyl and 7-hydroxymitragynine in some O.P.M.S.” products.[27] The Times names the Wyoming plaintiff Martian Sales. The association's status report names it Martin Sales Inc.[52][38]
The Times dates a turn to a day in August: “The federal position on MGPI began to shift Aug. 25, the day David and Maya Gabbay donated nearly $160,000 to the Republican National Committee, bringing their total for the year to $2.2 million.”[52] Federal Election Commission records list a $79,000 receipt by the Republican National Committee from David Gabbay of Dallas, dated August 25, 2026.[53] We have not yet totalled the couple's giving against the Times's figures.
On the White House, the record is the lobbying reports. In all three quarterly reports for 2026, Upstream Consulting names C. McClain Haddow as the association's lobbyist and lists the White House Office among the offices lobbied.[54][55] A report lists offices contacted. It does not say who was met or what was asked.
On October 30 the association wrote to the paper's publisher, A.G. Sulzberger, asking the Times to “publish a prominent and substantial correction, or retract its” story.[56] The letter does not take issue with the reporting on donations or lawsuits. Haddow's release says so: “This is not a disagreement about whether journalists should scrutinize government decisions, lobbying, or political contributions. Of course they should,” he said.[57] The complaint is about the rule, and it names two omissions. The first: “The most consequential omission is that the revised DEA proposal does not establish separate permissible concentration thresholds for 7-OH and MGPI.”[56] The second is the ratio test. Together, the letter says, they “substantially changes the regulatory approach and cannot accurately be described simply as an increase in the permissible amount of 7-OH.”[56] The association also asked the paper to “clarify that the October action remains a Notice of Intent rather than an effective final order”.[57]
On those three points the notice says what the association says it does. It covers the two compounds “when either substance alone, or their combined amount if both are present, is above a specified threshold”, and the ratio is a second, independent way in.[19] It is a notice of intent.[19] The syndicated copy calls it “the latest proposal” and a “new proposed order”. It does not mention the combined count or the ratio.[52] The letter puts the Times's characterization in quotation marks as a “political retreat.”[56] That phrase is not in the syndicated copy. The notice also contains what the story describes. For solids the concentration line is twice July's, and pseudoindoxyl would go from controlled at any amount to controlled above a threshold.[1][19][14] The notice itself says the two compounds “have supposedly been found in trace amounts in some botanical kratom products”.[19] Both descriptions rest on the same document. It does not say which one is right. The syndicated copy, archived on November 11, carries no correction.[52]
On November 15, 2026 CBS's 60 Minutes opened a report on the opioid crisis with kratom, with Jon Wertheim as correspondent.[22] Three things in it are new to this page.
The first is two resignations, explained by the people who resigned. The broadcast says Calley Means, until recently a senior advisor at HHS, and Makary “both told 60 Minutes they recently resigned from their posts in part because of recent changes to kratom policy shaped, as they say, by business interests, rather than public health”.[22] That is their account. The Finance Committee's release of August 5 gave flavored vapes as the issue Makary had argued.[51] The program also played Means on Joe Rogan's podcast earlier in the year: “The amount of lobbying on this was unrelenting”, and later in the same answer, “pushing from the West Wing to relax the standards”.[22] He named nobody. HHS declined an interview and said in a statement: “Neither political contributions nor outside pressure influenced our recommendation.”[22]
The second is lobbying money. The program said it found in public filings “a constant stream of cash”, much of it from the American Kratom Association, “earmarked to lobbying the FDA, HHS, the White House, and members of Congress”.[22] The filings bear that out. Lobbying Disclosure Act reports for the association as client come to about $3.6 million from 2016 through the third quarter of 2026, by our count with each quarter taken once after amendments. $800,000 of it was reported for 2025 and $710,000 for the first three quarters of 2026.[58] Since 2019 the reports of its longest-serving firm, Upstream Consulting, have listed the White House among the offices lobbied. The latest gives the issue as “Protect legal access for consumers to kratom products.” and lists both houses, the FDA, HHS and the “White House Office” as the offices lobbied.[55] A report lists offices contacted. It does not say who was met or what was asked. The association, in a statement to the program, stressed the line between natural kratom and “dangerous chemically manipulated products”.[22]
The third is political money from the Feel Free side. The program said Botanic Tonics and its founder Ross “donated nearly $1.2 million” to Kennedy's campaigns and the Make America Healthy Again PAC.[22] Federal Election Commission records come to that. MAHA PAC reported two receipts of $500,000 from Botanic Tonics LLC, on March 4 and April 9, 2026.[59] Contributions under Jerry W. Ross, employer Botanic Tonics, add $161,800 to Kennedy Victory Fund 2024 in January and February 2025 and $6,600 to Team Kennedy in September 2023.[60] The total is $1,168,400. The Times's $1 million is the PAC's part of it.[44] On the Homeland Security Secretary's stake, the broadcast reported that “Mullin confirmed the Botanic Tonics investment but denied lobbying”.[22]
Means's account describes pressure from the West Wing without naming anyone.
The claim that drug companies want 7-OH removed so a patented version can replace it circulates widely and has a documented substrate. The FDA's own kratom page says that “Drug companies that are interested in kratom-related drug development are encouraged to contact the relevant review division in the Center for Drug Evaluation and Research to answer questions related to their specific drug development program.”[61] A granted patent exists, titled “Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders”, assigned to Columbia University, the Research Foundation for Mental Hygiene and Memorial Sloan Kettering Cancer Center.[62] DEA's own order says the three scheduled derivatives came out of research: “The chemical scaffolds of mitragynine or 7-hydroxymitragynine were used in scientific research to develop mitragynine pseudoindoxyl, MGM-15, or MGM-16 via chemical modifications of purified isolates.”[14] Of the two MGM compounds it says: “In 2014, as part of a drug discovery research, MGM-15 and MGM-16 were developed as potent opioid agonists, with potential therapeutic utility for pain.”[11]
What the record does not contain is a company. The one firm that took a kratom alkaloid derivative into people, Kures, ran a single Phase 1 trial of a modified mitragynine in New Zealand in 2022.[63] Its parent's annual report states that “In July 2024, the Board of Directors for Kures determined it was in the best interests of the company to wind up operations and dissolve Kures through a Plan of Liquidation and Dissolution”, and that “Kures assigned to Columbia all of Kures' intellectual property rights that were filed during the term of the License Agreement and agreed that all licenses granted to Kures by Columbia are terminated.”[64] One company, Sparian Biosciences, says it is developing a kratom-derived candidate called SBS-226 with federal grant money, at a stage before any human trial.[65] The only mitragynine drug entering human trials in the United States belongs to the government. The National Institutes of Health announced on June 1, 2026 that “The IND paves the way for an NIH-led phase I clinical trial to evaluate mitragynine as a potential treatment for opioid use disorder.”[66] The release says “Researchers at NIH and the University of Florida developed the purified formulation of mitragynine to be used in the trial, as well as the preclinical work that led to the submission of the IND application.”[66] The registry entry, sponsored by the National Institute on Drug Abuse, describes the product: “MG001 is a formulation of mitragynine, a compound that comes from a plant called Mitragyna speciosa (sometimes known as kratom), which some people use on their own to help manage symptoms of opioid withdrawal.”[67] And both DEA documents record HHS telling DEA that nobody held an investigational or approved application for the substances being scheduled.[1][14] The FDA page adds that “There are no FDA-approved kratom drug products or over-the-counter drugs containing kratom that are legally on the market in the U.S.”[61]
So the pharmaceutical allegation, as of this writing, has patents and an open regulatory door behind it. It has no documented company or licence in front of it, and no official connected to one. Every dated, attributable allegation about money in this fight runs between kratom sellers.
The government has backed off before. In 2016 DEA announced it was “issuing this notice of intent to temporarily schedule the opioids mitragynine and 7-hydroxymitragynine, which are the main active constituents of the plant kratom, into schedule I”, which would have covered the leaf.[68] Six weeks later it withdrew, saying “DEA received numerous comments from the public on mitragynine and 7-hydroxymitragynine, including comments offering their opinions regarding the pharmacological effects of these substances.”[69] In 2018 the Assistant Secretary for Health rescinded a recommendation to schedule, writing, in a letter published by an advocacy site in 2021: “I now conclude that while mitragynine and 7-hydroxymitragynine have many properties of an opioid, scheduling these chemicals at this time in light of the underdeveloped state of the science would be premature.”[70] The 2026 action is narrower than the 2016 one. It names a threshold and leaves the leaf out.[1]

Figure 13. The 2016 notice, Docket DEA-442, which named mitragynine itself and so would have covered the leaf. DEA withdrew it on October 13, 2016.[68]
The death figures the government cites are its own, and both agencies attach qualifiers that the headlines drop. The FDA's July 2025 assessment, released with the scheduling recommendation, says this of its own case reports: “Although FDA's Adverse Event Reporting System (FAERS) has documented cases reporting adverse events (13 cases, including 2 deaths) suspected to involve 7-OH, ambiguity about the contributory role of 7-OH from uncharacterized products or concomitant medications and underlying disease limits interpretation. Therefore, we do not include further analysis of these FAERS cases here.”[71] Of the DEA's toxicology data it says “it generally cannot be discerned whether deaths are related to mitragynine, 7-OH, or mitragynine pseudoindoxyl, or some combination thereof”.[71] The Commissioner's letter to doctors the same day gave no death count. Its quantified claim was potency: “one study in the Journal of Medicinal Chemistry found 7-OH to be 13 times more potent than morphine”.[72] Seven months later the DEA's notice gave these figures. From the FDA adverse event database, queried February 27, 2026: “To date, 9 cases within the FAERS database have resulted in death.”[1] From DEA's toxicology programme, which “has identified 7-hydroxymitragynine in 85 cases since 2019”: “Of these, 55 were fatal and 30 were non-fatal cases.”[1] The next sentence is the one to read with those counts: “Samples often contained other related alkaloids (mitragynine and mitragynine pseudoindoxyl) or other drug classes, such as opioids (e.g. fentanyl), benzodiazepines (e.g. bromazolam), and ketamine.”[1] DEA also notes a measurement problem: “Public health assessment is further complicated because 7-hydroxymitragynine is a known metabolite of mitragynine, making it difficult to distinguish between the ingestion of M. speciosa and other isolated 7-hydroxymitragynine products.”[1] HART's sentence that “No confirmed deaths have been attributed solely to 7-OH” is consistent with those passages, and so is the government's count.[34][1]

Figure 14. Cover of the FDA assessment released on July 29, 2025. Inside, it declines to analyse its own 13 adverse event cases because of what it calls ambiguity about 7-OH’s role.[71]
One last thing about the label. ‘Gas station heroin’ is a phrase, not a pharmacology. The FDA used it in May 2025 for tianeptine, a drug that is, in the FDA's words, often called that “because of its availability in gas station stores, is not approved by the FDA for any use”.[73] Tianeptine is a different molecule from a different class. The FDA notes that “In some countries, tianeptine is licensed and marketed as an atypical antidepressant.”[73] DEA's proposed rule on it says “Tianeptine is structurally and pharmacologically referred to as a tricyclic antidepressant.”[74] Its opioid activity was established in 2014, when Gassaway and colleagues wrote: “Herein, we report the characterization of tianeptine as a μ-opioid receptor (MOR) agonist.”[75] 7-OH, by contrast, “is a psychoactive alkaloid found in Mitragyna speciosa” that DEA says “shares health risks similar to other mu-opioid receptor agonists, such as morphine (schedule II)”.[1] The same phrase has been applied to both, and the transfer is visible in the record. On the day of the announcement NBC News wrote of gas station products, not gas station heroin, and quoted Makary: “We are going after the killer first”.[76] The next day a Philadelphia station reported a poison-centre clinician's comparison: “He compared 7-OH to other unregulated substances like tianeptine, often referred to as "gas station heroin."”[77] The phrase still belonged to tianeptine. Neither Makary nor Kennedy used it in the six primary documents checked for this page.[2][72][13] Kennedy reached for the gas station image when announcing the 7-OH action.[4] The pro-scheduling lobbying client is named Stop Gas Station Heroin LLC.[43] The Daily Beast's headline on the Mullin disclosure called Botanic Tonics, a seller of leaf kratom drinks, a ‘Gas Station Heroin’ company.[49] A phrase that covers an antidepressant as readily as a kava drink is describing a shelf.
Changes
- 2026-11-18, the Times story. Added the New York Times story of October 28 on pseudoindoxyl and the Gabbay donations, the American Kratom Association's demand of October 30 for a correction or retraction, and what the Federal Register, the court filings, Federal Election Commission records and lobbying reports show on each point.
- 2026-11-18, after the broadcast. Added what CBS's 60 Minutes of November 15 put on the record: the Means and Makary resignations in their own account, HHS's statement, and the program's figures on lobbying and donations, each checked against Lobbying Disclosure Act and Federal Election Commission records. Noted that the program's twentyfold figure is not a factor either DEA notice gives.
- 2026-11-18. Brought up to date after the August order. New dated entries for the senators' letters of October 7 and November 16, HHS's October recommendation, DEA's two notices of October 14 (a new threshold, still unpublished as an order on November 18), and Louisiana's emergency rule. Corrected the line that called the American Kratom Association the only party to have sued: it is one of three plaintiffs with the same counsel. Two figures added. Cut one sentence quoting Kennedy from The Daily Beast of August 26, 2026, because the live page no longer carries the quote; it returns if an archived copy confirms it.
- 2026-10-07. Figures added: 12 pictures of the documents this page quotes, among them the first pages of the DEA notices and order, the senators’ letters, H.R. 8000, the CRS sidebar, a Form 990 summary and a lobbying report.
References
- Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I (notice of intent, 91 FR 40917, Docket DEA-1570) — Drug Enforcement Administration, Federal Register, 2026-07-06
- FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers — US Food and Drug Administration, 2025-07-29
- FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine — US Food and Drug Administration, 2025-07-15
- Feds launch crackdown on kratom byproduct — Axios, 2025-07-29 (Wayback Machine copy)
- Meeting on kratom canceled after call from HHS Secretary RFK Jr., but DeWine still wants Ohio ban — Ohio Statehouse News Bureau, 2025-09-02
- FDA Seizes 7-OH Opioids to Protect American Consumers — US Food and Drug Administration, 2025-12-02
- Letter from eleven senators to FDA Commissioner Makary on kratom scheduling — Office of Senator Pete Ricketts, 2026-03-18
- H.R. 8000, END 7-OH Act, 119th Congress, as introduced — US Government Publishing Office, 2026-03-19
- Senator Marshall Urges Immediate DEA Action on 7-OH Substances — Office of Senator Roger Marshall, 2025-12
- Trump's Endorsement of 'Natural 7-OH' Stirs Debate in Kratom Industry — Pain News Network, 2026-05-13
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (notice of intent, 91 FR 40909, Docket DEA-1644) — Drug Enforcement Administration, Federal Register, 2026-07-06
- Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Information (91 FR 41049, Docket HHS-OASH-2026-0232) — HHS Office of the Assistant Secretary for Health, Federal Register, 2026-07-06
- HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products — US Department of Health and Human Services, 2026-07-01 (Wayback Machine copy)
- Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (temporary scheduling order, 91 FR 54948) — Drug Enforcement Administration, Federal Register, 2026-08-26
- Justice Department Announces Emergency Scheduling of Three Potent Opioid Compounds — US Department of Justice, Office of Public Affairs, 2026-08-25
- Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Extension of Comment Period (91 FR 55104) — HHS Office of the Assistant Secretary for Health, Federal Register, 2026-08-26
- Kratom and 7-OH should be regulated, experts agree. They're split on how — STAT, 2026-09-30 (Wayback Machine copy)
- Letter from Senators Charles E. Grassley, Susan M. Collins and Michael S. Lee to DEA Administrator Terrance Cole and Acting FDA Commissioner Kyle Diamantas on 7-OH — Office of Senator Chuck Grassley, 2026-10-07
- Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I (notice of intent, Docket DEA-1570, FR Doc. 2026-20943, 91 FR 65370) — Drug Enforcement Administration, Federal Register, 2026-10-14
- Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I (notice of intent, Docket DEA-1644, FR Doc. 2026-20942, 91 FR 65381) — Drug Enforcement Administration, Federal Register, 2026-10-14
- HHS Recommends Science-Based Thresholds to Target Dangerous Enhanced Kratom Products — US Department of Health and Human Services, 2026-10-09 (Wayback Machine copy)
- 60 Minutes Transcript: Kratom, often sold as an herbal supplement, can pose serious health risks (correspondent Jon Wertheim, broadcast 2026-11-15) — CBS News, 2026-11-15 (Wayback Machine capture 2026-11-17)
- Federal Register search: documents containing the term 7-hydroxymitragynine — Office of the Federal Register, queried 2026-11-18
- Declaration of Emergency, Department of Health, Office of Public Health: Added Controlled Dangerous Substances (LAC 46:LIII.2704), 2610#001, signed by Secretary Bruce D. Greenstein — Louisiana Register, vol. 52, October 2026 (Wayback Machine copy of the Word file)
- Letter from Senator Charles E. Grassley and seven colleagues to DEA Administrator Terrance Cole and Acting FDA Commissioner Kyle Diamantas on the revised 7-OH threshold — Office of Senator Chuck Grassley, 2026-11-16
- Temporary Control of 7-Hydroxymitragynine (7-OH) and Related Substances Under the Controlled Substances Act (LSB11457) — Congressional Research Service, 2026-07-17
- New Hope Botanicals, LLC v. United States Drug Enforcement Administration, No. 5:26-cv-05022 (C.D. Cal.), ECF No. 1, Complaint (RECAP copy) — US District Court for the Central District of California, filed 2026-08-31, RECAP archive, Free Law Project
- American Kratom Association Files Federal Lawsuit to Protect Natural Kratom Consumers from Misapplication of DEA Temporary Scheduling Order — American Kratom Association, 2026-08-27
- American Kratom Association, EIN 47-2208981, Form 990 data — ProPublica Nonprofit Explorer
- DEA Will Classify 7-OH as Illegal Drug — Pain News Network, 2026-07-01
- Global Kratom Coalition Inc, Form 990 data — ProPublica Nonprofit Explorer
- Global Kratom Coalition Endorses Rep. Bilirakis' Bill to Schedule Concentrated Synthetic 7-OH — Global Kratom Coalition via EZ Newswire, 2026-03-26
- Holistic Alternative Recovery Trust Inc, Form 990 data — ProPublica Nonprofit Explorer
- HART Responds to DEA Notice of Intent to Temporarily Schedule 7-OH — Holistic Alternative Recovery Trust, 2026-07-02
- Kratom Lobby Fights FDA Regulation Push — Legis1, 2026-07
- As dangerous kratom products go unregulated, lobbyists write the laws — Tampa Bay Times, Deadly Dose investigation, 2023
- The Scientist Trying to Keep Kratom Legal Has Not Disclosed Longstanding Ties to Kratom Lobbyists — ProPublica, 2025
- American Kratom Association v. United States Drug Enforcement Administration, No. 1:26-cv-02997 (D.D.C.), ECF No. 16, Joint Status Report (RECAP copy) — US District Court for the District of Columbia, filed 2026-09-08, RECAP archive, Free Law Project
- New Hope Botanicals, LLC v. United States Drug Enforcement Administration, No. 5:26-cv-05022 (C.D. Cal.), ECF No. 40, Civil Minutes, Judge Jesus G. Bernal (RECAP copy) — US District Court for the Central District of California, 2026-09-28, RECAP archive, Free Law Project
- Senator’s inquiry questions kratom industry’s influence on Trump administrations — NutraIngredients, 2026-08-26
- Conflicts abound in new Florida push against kratom compound (opinion) — Florida Politics, Peter Schorsch, 2025-02
- Global Kratom Coalition Ends BGR Government Affairs Contract — Legis1, 2026-06-16
- Lobbying report, Checkmate Government Relations for client Stop Gas Station Heroin LLC, 4th quarter 2025 — US Senate Office of Public Records, Lobbying Disclosure Act filing
- How an addictive gas station drug found allies in Trump's cabinet (New York Times, Kenneth P. Vogel and Christina Jewett, 2026-06-15; syndicated copy) — The Philadelphia Inquirer, 2026-06-16
- 'Enormous Confusion' as Deadline Nears for 7-OH Kratom Ban — Pain News Network, 2026-08-03
- More than 24,300 Americans urge DEA to reject 7-OH ban — Holistic Alternative Recovery Trust, 2026-07-30
- 7-HOPE Alliance Applauds 7-OH Comment Extension, Calls on HHS and DEA to Reconsider and Review Emerging Science — 7-HOPE Alliance via EZ Newswire, 2026-09-03
- R Street Comments on Placement of 7-OH on Schedule I — R Street Institute, 2026-07-31
- ICE Barbie Successor Has Up to $1M in Shares of 'Gas Station Heroin' Company — The Daily Beast, 2026-05-19
- Letter from Senator Ron Wyden to Jerry Ross, Botanic Tonics — US Senate Committee on Finance, 2026-08-03
- Wyden Investigates Trump and RFK Jr. Corruption Favoring Big Tobacco and Kratom Companies — US Senate Committee on Finance, Ranking Member, 2026-08-05
- Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying (New York Times, Christina Jewett, 2026-10-28; syndicated copy, archived 2026-11-11) — GV Wire, 2026-10-28
- Individual contributions from David Gabbay (Dallas, TX), 2025-2026 cycle: Republican National Committee, $79,000 dated 2026-08-25 — Federal Election Commission, read 2026-11-18
- Lobbying Disclosure Act filings for client American Kratom Association, filing year 2026 (API query, 23 filings: Upstream Consulting's Q1-Q3 reports name C. McClain Haddow and list the White House Office), read 2026-11-18 — US Senate Office of Public Records, lda.gov
- Lobbying report, Upstream Consulting, Inc. for client American Kratom Association, 3rd quarter 2026 — US Senate Office of Public Records, Lobbying Disclosure Act filing
- Letter from Mac Haddow, American Kratom Association, to A.G. Sulzberger, publisher of The New York Times: formal request for significant correction or retraction of the October 28, 2026 article — American Kratom Association, 2026-10-30 (Wayback Machine copy)
- American Kratom Association Demands Major Correction or Full Retraction of Misleading New York Times Report on DEA Opioid Scheduling — American Kratom Association via EZ Newswire, on fortune.com, 2026-10-30 (Wayback Machine copy)
- Lobbying Disclosure Act filings for client American Kratom Association, 2016 to third quarter 2026 (API query, 146 filings), read 2026-11-18 — US Senate Office of Public Records, lda.gov
- Receipts of MAHA PAC (C00821439) from Botanic Tonics LLC, 2025-2026 cycle: $500,000 on 2026-03-04 and $500,000 on 2026-04-09, non-contribution account — Federal Election Commission, read 2026-11-18
- Individual contributions by Jerry W. Ross, employer Botanic Tonics: Kennedy Victory Fund 2024 (C00883751) $146,300.01 on 2025-01-02 and $15,499.99 on 2025-02-05; Team Kennedy (C00836916) two of $3,300 on 2023-09-19 — Federal Election Commission, read 2026-11-18
- FDA and Kratom — US Food and Drug Administration, public health focus page
- US20210179619A1 / US11760758B2, Mitragynine analogs for the treatment of pain, mood disorders and substance use disorders — Google Patents (assignees Columbia University, Research Foundation for Mental Hygiene, Memorial Sloan Kettering Cancer Center)
- NCT05114265: Safety, Tolerability, Pharmacokinetics, Analgesic and Respiratory Effect of KUR-101 in Healthy Adult Participants — ClinicalTrials.gov, sponsor Kures, Inc.
- ATAI Life Sciences N.V., Form 10-K for the fiscal year ended December 31, 2024 — US Securities and Exchange Commission, EDGAR, filed 2025-03-17
- Sparian Biosciences Awarded $19.5 Million Five-Year NIH/NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/Opiate Withdrawal Syndrome Through Phase 1 Clinical Development — Sparian Biosciences via GlobeNewswire, 2024-11-14
- NIH research clears way for study of experimental treatment for opioid use disorder — National Institutes of Health, 2026-06-01 (Wayback Machine copy)
- NCT07204171: Phase 1 Study of Oral MG001 — ClinicalTrials.gov, sponsor National Institute on Drug Abuse
- Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine Into Schedule I (notice of intent, 81 FR 59929) — Drug Enforcement Administration, Federal Register, 2016-08-31
- Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7-Hydroxymitragynine Into Schedule I (81 FR 70652) — Drug Enforcement Administration, Federal Register, 2016-10-13
- Letter from Assistant Secretary for Health Brett P. Giroir to DEA Acting Administrator Uttam Dhillon, 2018-08-16, rescinding the 2017 scheduling recommendation (transcription) — Kratom Science, transcription published 2021-02-12
- 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat — US Food and Drug Administration, Center for Drug Evaluation and Research, July 2025 (Wayback Machine copy of the PDF)
- Letter to health care professionals on 7-hydroxymitragynine (7-OH), signed by Commissioner Martin A. Makary — US Food and Drug Administration, 2025-07-29 (Wayback Machine copy of the PDF)
- New “Gas Station Heroin” Tianeptine Product Trend (letter to health care professionals) — US Food and Drug Administration, 2025-05-08
- Schedules of Controlled Substances: Placement of Tianeptine in Schedule I (notice of proposed rulemaking, 91 FR 42150) — Drug Enforcement Administration, Federal Register, 2026-07-08
- The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist — Translational Psychiatry, 2014, via PubMed Central
- FDA asks Justice Department to classify gas station products with opioid-like effects as illicit substances — NBC News, 2025-07-29
- FDA urges crackdown on 7-OH, a potent opioid-like substance sold in gas stations — 6abc Philadelphia (WPVI), 2025-07-30
Comments
Sign in to join the conversation.
No comments yet.